These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35348408)

  • 61. Real-world Safety and Efficacy of Indacaterol/Glycopyrronium in Japanese Patients with Chronic Obstructive Pulmonary Disease: A 52-week Post-marketing Surveillance.
    Kato C; Yoshisue H; Nakamura N; Sasajima T
    Intern Med; 2022 Mar; 61(6):789-800. PubMed ID: 34483208
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD.
    Doherty DE; Tashkin DP; Kerwin E; Knorr BA; Shekar T; Banerjee S; Staudinger H
    Int J Chron Obstruct Pulmon Dis; 2012; 7():57-71. PubMed ID: 22334769
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Long-term safety of mometasone furoate administered via a dry powder inhaler in children: Results of an open-label study comparing mometasone furoate with beclomethasone dipropionate in children with persistent asthma.
    Noonan M; Leflein J; Corren J; Staudinger H
    BMC Pediatr; 2009 Jul; 9():43. PubMed ID: 19594937
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β
    Devillier P; Humbert M; Boye A; Zachgo W; Jacques L; Nunn C; West S; Nicholls A; Antoun Z; Spinu L; Grouin JM
    Respir Med; 2018 Aug; 141():111-120. PubMed ID: 30053956
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Indacaterol/glycopyrronium: a dual bronchodilator for COPD.
    Banerji D; Fogel R; Patalano F
    Drug Discov Today; 2018 Jan; 23(1):196-203. PubMed ID: 29079130
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
    Hohlfeld JM; Vogel-Claussen J; Biller H; Berliner D; Berschneider K; Tillmann HC; Hiltl S; Bauersachs J; Welte T
    Lancet Respir Med; 2018 May; 6(5):368-378. PubMed ID: 29477448
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pharmacokinetics of mometasone furoate delivered via two dry powder inhalers.
    Vaidya S; Ziegler D; Tanase AM; Malmqvist U; Kanniess F; Hederer B; Hosoe M
    Pulm Pharmacol Ther; 2021 Oct; 70():102019. PubMed ID: 33771722
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids.
    Nathan RA; Nolte H; Pearlman DS;
    Allergy Asthma Proc; 2010; 31(4):269-79. PubMed ID: 20678306
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma.
    Sharpe M; Jarvis B
    Drugs; 2001; 61(9):1325-50. PubMed ID: 11511026
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical Interpretation of Efficacy Outcomes in Pharmacological Studies on Triple Fixed-Dose Combination Therapy for Uncontrolled Asthma: Assessment of IRIDIUM and ARGON Studies.
    Rogliani P; Calzetta L
    J Exp Pharmacol; 2022; 14():1-5. PubMed ID: 35046733
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD.
    Chan MC; Tan EC; Yang MC
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1079-1088. PubMed ID: 29670344
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Improvement in health status with once-daily indacaterol/glycopyrronium 110/50 μg in COPD patients: real-world evidence from an observational study in Ireland.
    O'Doherty B; Dorman J; McGrath K; Kelly K; Molony D; Lacey S; Whelan S; Schmid S; Sullivan S
    Ir J Med Sci; 2019 Nov; 188(4):1251-1259. PubMed ID: 30924006
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.
    Ulrik CS
    Int J Chron Obstruct Pulmon Dis; 2014; 9():331-8. PubMed ID: 24729699
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study.
    Ohta K; Ichinose M; Tohda Y; Engel M; Moroni-Zentgraf P; Kunimitsu S; Sakamoto W; Adachi M
    PLoS One; 2015; 10(4):e0124109. PubMed ID: 25894430
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Population pharmacokinetics of IND/GLY (indacaterol/glycopyrronium) in COPD patients.
    Demin I; Bartels C; Graham G; Bieth B; Gautier A; Tillmann HC; Sechaud R
    Int J Clin Pharmacol Ther; 2016 Jun; 54(6):405-15. PubMed ID: 27049057
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
    Wedzicha JA; Banerji D; Chapman KR; Vestbo J; Roche N; Ayers RT; Thach C; Fogel R; Patalano F; Vogelmeier CF;
    N Engl J Med; 2016 Jun; 374(23):2222-34. PubMed ID: 27181606
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials.
    Tashkin DP; Doherty DE; Kerwin E; Matiz-Bueno CE; Knorr B; Shekar T; Gates D; Staudinger H
    Int J Chron Obstruct Pulmon Dis; 2012; 7():73-86. PubMed ID: 22334770
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Mometasone furoate/formoterol in the treatment of persistent asthma.
    Berger WE
    Expert Rev Respir Med; 2011 Dec; 5(6):739-46. PubMed ID: 22082160
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Inhaled Budesonide vis-à-vis Inhaled Mometasone in Chinese Children with Mild Persistent Asthma: A Single-Center, Retrospective Study.
    Gao P; Ding Y; Yin B; Gu H
    Pharmacology; 2021; 106(11-12):616-622. PubMed ID: 34518479
    [TBL] [Abstract][Full Text] [Related]  

  • 80. QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease.
    Frampton JE
    Drugs; 2014 Mar; 74(4):465-88. PubMed ID: 24604791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.